Entacapone

Names

[ Name ]:
Entacapone

[Synonym ]:
(E)-2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide
(2E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylacrylamide
Comtan
Comtes
(2Z)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylacrylamide
OR-611
2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide
MFCD00866580
2-Propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-, (2E)-
(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
Comtess
(E)-a-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
Entacapone
2-Propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-, (2Z)-

Biological Activity

[Description]:

Entacapone is a specific, potent, peripherally acting catechol-O-methyltransferase (COMT) inhibitor with IC50 of 151 nM for PD treatment.IC50 Value: 151 nMTarget: COMTin vitro: Entacapone inhibits catechol-O-methyltransferase(COMT) with similar IC50 in different tissues including live, duodenum, kidney and lung, but entacapone is more active than tolcapone in those tissues. Entacapone (< 100 μM) is a potent inhibitor of α-syn and β-amyloid (Aβ) oligomerization and fibrillogenesis, and also protects against extracellular toxicity induced by the aggregation of both proteins in PC12 cells.in vivo: Levodopa/carbidopa/entacapone has been shown to improve the pharmacokinetic profile of levodopa and provide superior symptomatic control compared with conventional levodopa/dopa decarboxylase inhibitor therapy. We report four case histories describing clinical experience of using levodopa/carbidopa/entacapone 200/50/200 mg, one of the latest doses of this formulation, in a range of patients with Parkinson's disease. These cases illustrate that levodopa/carbidopa/entacapone 200/50/200 mg provides improvements in symptomatic control.Clinical trial: The combination product carbidopa/levodopa/entacapone (CLE) was approved in 2003 for the treatment of PD patients.

[Related Catalog]:

Signaling Pathways >> Metabolic Enzyme/Protease >> COMT

Signaling Pathways >> Neuronal Signaling >> COMT

Research Areas >> Neurological Disease

[References]

[1]. Piccini P, Brooks DJ, Korpela K, The catechol-O-methyltransferase(COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000 May;68(5):589-94.

[2]. Di Giovanni S, Eleuteri S, Paleologou KE, Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity. J Biol Chem. 2010 May 14;285(20):1494

[3]. Sethi KD, Hauser RA, Isaacson SH, Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo 200) in the treatment of Parkinson's disease: a case series. Cases J. 2009 Jul 30;2:7134.

[4]. Poulopoulos M, Waters C. Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease. Core Evid. 2010 Jul 27;5:1-10.

[Related Small Molecules]

Serotonin hydrochloride | Tolcapone | Opicapone | Flopropione | Entacapone sodium salt

Chemical & Physical Properties

[ Density]:
1.4±0.1 g/cm3

[ Boiling Point ]:
526.6±50.0 °C at 760 mmHg

[ Melting Point ]:
162-1630C

[ Molecular Formula ]:
C₁₄H₁₅N₃O₅

[ Molecular Weight ]:
305.286

[ Flash Point ]:
272.3±30.1 °C

[ Exact Mass ]:
305.101166

[ PSA ]:
130.38000

[ LogP ]:
2.38

[ Vapour Pressure ]:
0.0±1.4 mmHg at 25°C

[ Index of Refraction ]:
1.642

[ Storage condition ]:
-20°C Freezer

MSDS

Click to get detail MSDS

Safety Information

[ Hazard Codes ]:
Xn,T,F

[ Risk Phrases ]:
R10:Flammable. R20/21/22:Harmful by inhalation, in contact with skin and if swallowed . R37/38:Irritating to respiratory system and skin . R41:Risk of serious damage to eyes. R62:Possible risk of impaired fertility. R38:Irritating to the skin. R36/37/38:Ir

[ Safety Phrases ]:
S26-S36-S39-S45-S36/37/39-S16

[ RIDADR ]:
UN 1986 3/PG 3

[ WGK Germany ]:
1

[ RTECS ]:
KM5250000

[ Packaging Group ]:
III

[ Hazard Class ]:
3

[ HS Code ]:
2942000000

Synthetic Route

Click to get detail synthetic route

Customs

[ HS Code ]: 2942000000

Articles

Dog UDP-glucuronosyltransferase enzymes of subfamily 1A: cloning, expression, and activity.

Drug Metab. Dispos. 43(1) , 107-18, (2014)

Understanding drug glucuronidation in the dog, a preclinical animal, is important but currently poorly characterized at the level of individual enzymes. We have constructed cDNAs for the 10 dog UDP-gl...

Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.

Parkinsonism Relat. Disord. 20(12) , 1335-40, (2014)

IPX066, an investigational extended-release carbidopa-levodopa (CD-LD) preparation, has demonstrated a rapid attainment and prolonged maintenance of therapeutic LD plasma concentrations in advanced Pa...

Entacapone and prostate cancer risk in patients with Parkinson's disease.

Mov. Disord 30(5) , 724-8, (2015)

The association between Parkinson's disease (PD) and prostate cancer, both common in elderly men, is disputable. In the STRIDE-PD study, prostate cancer developed in 9 patients (3.7%) receiving levodo...

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.